AstraZeneca’s liver cancer therapy combo slows disease progression in late-stage trial

April 2 (Reuters) – AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a ​common liver cancer lived before their disease worsened, ‌in a late-stage trial.

Here are the key details from the top-line results of the trial and analysts’ forecasts:

(Reporting by Prerna Bedi and Pushkala Aripaka in Bengaluru; Editing ​by Shinjini Ganguli)